We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.
In cooperation with Association of Corporate Counsel
  Request new password

Search results

Order by most recent / most popular / relevance

Results: 1-10 of 431

Patent not eligible for listing: patent claiming one medicinal ingredient,but directed to a fixed-dose combination of medicines

  • Borden Ladner Gervais LLP
  • -
  • Canada
  • -
  • October 15 2014

This was an appeal from two decisions for three proceedings before Prothonotary Milczynski, in which she determined that a patent could not be listed

Dow prevails over Nova in polymer patent suit

  • Smart & Biggar/Fetherstonhaugh
  • -
  • Canada
  • -
  • October 8 2014

The Dow Chemical Company (“Dow”) has prevailed in a Canadian patent infringement suit against Nova Chemicals Corporation (“Nova”) relating to Nova’s

B.C. Supreme Court breathes life into new breed of potential pharma-related class action whereby innovator profits are at risk

  • McCarthy Tétrault LLP
  • -
  • Canada
  • -
  • August 22 2014

In Canada, innovator drug companies can protect their market exclusivity from generic copycats by asserting patents against the generic manufacturer

Causes of action found against Pfizer for a BC class-action certification based on the VIAGRA patent

  • Borden Ladner Gervais LLP
  • -
  • Canada
  • -
  • August 14 2014

Pfizer had a Canadian patent for VIAGRA that was found to not comply with the disclosure requirement by the Supreme Court in an earlier PM(NOC

FCA refuses to stay injunction order

  • Borden Ladner Gervais LLP
  • -
  • Canada
  • -
  • July 10 2014

Janssen and Abbvie were involved in a patent infringement action. Abbvie was successful in its claim for infringement, and the patent was held to be

The Federal Court finds two generic company's allegations to be unjustified

  • Borden Ladner Gervais LLP
  • -
  • Canada
  • -
  • July 10 2014

Two PM(NOC) decisions relating to the same patent were recently released by the Federal Court. In both cases, the applications were allowed

Patent held invalid for not meeting promise of improved therapeutic profile

  • Borden Ladner Gervais LLP
  • -
  • Canada
  • -
  • July 10 2014

Apotex was successful in the previous NOC Proceeding. It came to market with an esomeprazole product. AstraZeneca sued for patent infringement and

Still safe the experimental use exception to anticipation

  • Smart & Biggar/Fetherstonhaugh
  • -
  • Canada
  • -
  • July 10 2014

Canada's laws provide a one-year grace period for public disclosures by the applicant (or by a person who obtained knowledge of an invention from the

Pharma in brief - Federal Court of Appeal overturns Federal Court decision and dismisses application for prohibition order

  • Norton Rose Fulbright Canada LLP
  • -
  • Canada
  • -
  • July 2 2014

Pharmascience Inc. (Pharmascience) appealed from the decision of Justice O’Keefe of the Federal Court (reported as AstraZeneca Canada Inc. v

Federal Court grants injunction that allows infringing biologic drug to stay on the market

  • Norton Rose Fulbright Canada LLP
  • -
  • Canada
  • -
  • June 20 2014

Case: AbbVie Corporation, AbbVie Deutschland GMBH & Co. KG and AbbVie Biotechnology Ltd. v. Janssen Inc., 2014 FC 489 Drug: Ustekinumab (STELARA®